Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06063473 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
A Phase 1 study of Acne Vulgaris, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 762
- Enrollment target
- 1
- Study location
NCT06063473 is a Phase 1 study of Acne Vulgaris that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 762 participants, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (189% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06063473, a Phase 1 study of Acne Vulgaris, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 762 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Trifarotene Cream 0.005%
- DRUG AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
Study Locations (1)
New York
- Taro Pharmaceuticals USA Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 762 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2023-07-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06063473
The ClinicalTrials.gov registry entry for NCT06063473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 762 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (189% higher). The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06063473 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06063473 about?
NCT06063473 is a clinical study titled "A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris". To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
What is the current status of trial NCT06063473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 762 participants. The study started on 2023-02-22. Estimated completion is 2023-07-13.
What conditions does trial NCT06063473 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT06063473?
The interventions under investigation include: Placebo (DRUG), Trifarotene Cream 0.005% (DRUG), AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories) (DRUG).
Who is sponsoring clinical trial NCT06063473?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06063473 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
RECRUITING · Phase 1
-
Lipidome and Microbiome Profile of Acne
ACTIVE NOT RECRUITING · Phase 1
-
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
COMPLETED · Phase 1
-
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
COMPLETED · Phase 1
-
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
COMPLETED · Phase 1
-
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.